Alpha-Lipoic Acid (ALA)
A unique universal antioxidant that functions in both fat-soluble and water-soluble environments, regenerating other antioxidants. One of the most evidence-backed supplements for diabetic neuropathy.
What is Alpha-Lipoic Acid (ALA)?
Alpha-lipoic acid (ALA) is a naturally occurring dithiol compound that functions as both a mitochondrial cofactor and a universal antioxidant, uniquely active in both aqueous and lipid environments throughout the body.
Known Health Benefits
How It Works
ALA serves as a cofactor for mitochondrial alpha-keto acid dehydrogenase complexes (pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase), which are critical entry points for the Krebs cycle. Once reduced to dihydrolipoic acid (DHLA) by mitochondrial dihydrolipoamide dehydrogenase, the ALA/DHLA redox couple becomes the most versatile biological antioxidant system. DHLA regenerates oxidized glutathione, vitamin C (dehydroascorbate to ascorbate), and vitamin E (tocopheroxyl radical to alpha-tocopherol), effectively recycling the entire antioxidant network. ALA activates AMPK in skeletal muscle, enhancing GLUT4 translocation and glucose uptake independent of insulin — explaining its blood sugar-lowering effects. For neuropathy, ALA improves nerve blood flow by enhancing endothelial nitric oxide production, reduces oxidative stress in nerve tissue, and inhibits advanced glycation end-product (AGE) formation. The R-enantiomer is the biologically active form, exhibiting 40–50% higher bioavailability and mitochondrial affinity than racemic (R,S) ALA.
What Research Says
The ALADIN trial (Ziegler et al., Diabetologia, 1995) was the first large RCT demonstrating IV ALA at 600 mg/day significantly reduced neuropathic symptoms in diabetic patients. The NATHAN 1 trial (Ziegler et al., Diabetes Care, 2011) confirmed oral ALA at 600 mg/day for 4 years improved neuropathic deficits and nerve conduction. A meta-analysis by Han et al. (European Journal of Endocrinology, 2012) of 15 RCTs found ALA significantly improved nerve conduction velocity and neuropathic symptoms. For metabolic health, a meta-analysis by Akbari et al. (Clinical Nutrition, 2018) found ALA supplementation significantly reduced fasting glucose, insulin, HOMA-IR, and HbA1c. Carbonelli et al. (Journal of Medical Food, 2010) reported ALA at 800 mg/day produced significant weight loss (8% body weight) in obese individuals over 4 months.
Active Compounds
R-alpha-lipoic acid (R-ALA), S-alpha-lipoic acid, dihydrolipoic acid (DHLA)
Forms & Bioavailability
Oral bioavailability is approximately 30% due to first-pass metabolism. R-ALA has 40–50% higher peak plasma levels than racemic ALA. Food reduces absorption by 30% — take on an empty stomach. Peak blood levels occur within 30–60 minutes of oral dosing.
Dosage Guidance
| Use Case | Dosage |
|---|---|
| General antioxidant support | 300 mg R-ALA/day |
| Diabetic neuropathy | 600 mg/day racemic ALA |
| Blood sugar support | 300–600 mg/day |
| Weight management (adjunct) | 600–800 mg/day |
Always consult a healthcare provider for personalized dosing.
Natural Food Sources
- Organ meats (kidney, heart, liver)
- Broccoli
- Spinach
- Tomatoes
- Brussels sprouts
- Red meat
Potential Side Effects
Nausea, GI upset; may significantly lower blood sugar — monitor if diabetic
Who Should Avoid It
- Thiamine (B1) deficiency (ALA may worsen — supplement B1 first)
- Diabetes with tight glycemic control (risk of hypoglycemia)
- Pre-surgery (discontinue 2 weeks prior due to blood sugar effects)
- Heavy alcohol use (may compound B1 deficiency)
Pregnancy & Lactation
Limited human pregnancy safety data. ALA crosses the placenta and has been used in some gestational diabetes studies without reported adverse effects, but it is not routinely recommended during pregnancy. Consult a healthcare provider.
Known Drug Interactions
May significantly enhance insulin and diabetes medications; may interact with thyroid medications
Evidence Classification
Supported by randomized controlled trials (RCTs), systematic reviews, or meta-analyses published in peer-reviewed journals.
Frequently Asked Questions
What is the difference between R-ALA and regular ALA?
Regular ALA supplements are racemic (50% R-ALA, 50% S-ALA). R-ALA is the biologically active form produced by the body, with 40–50% better absorption and stronger mitochondrial affinity. S-ALA may actually compete with R-ALA for absorption. Stabilized R-ALA (sodium R-lipoate) is the optimal supplemental form.
Can ALA help with diabetic neuropathy?
Yes. ALA is one of the most evidence-backed supplements for diabetic neuropathy, with multiple large RCTs (ALADIN, NATHAN 1) demonstrating significant improvement in pain, burning, numbness, and nerve conduction. Germany approves ALA as a treatment for diabetic neuropathy.
Why should ALA be taken on an empty stomach?
Food reduces ALA absorption by approximately 30%. Taking it 30 minutes before meals on an empty stomach maximizes peak plasma levels and ensures optimal bioavailability. This is especially important for the R-ALA form.
Does ALA interact with diabetes medications?
Yes. ALA enhances insulin sensitivity and glucose uptake via AMPK activation, which can additively lower blood sugar when combined with insulin, metformin, or sulfonylureas. Blood sugar monitoring and potential medication dose reduction are essential.
How long does ALA take to improve neuropathy symptoms?
Most clinical trials show symptomatic improvement within 3–5 weeks at 600 mg/day. Maximum benefit typically occurs after 3–6 months of continuous use. Some nerve conduction improvements require longer treatment periods.
References
- Treatment of symptomatic diabetic neuropathy with alpha-lipoic acid (ALADIN Study). Ziegler D, Hanefeld M, Ruhnau KJ, et al.. Diabetologia (1995)View study
- Treatment of symptomatic diabetic polyneuropathy with alpha-lipoic acid (NATHAN 1). Ziegler D, Low PA, Litchy WJ, et al.. Diabetes Care (2011)View study
- Alpha-lipoic acid for diabetic peripheral neuropathy: meta-analysis. Han T, Bai J, Liu W, Hu Y. European Journal of Endocrinology (2012)View study
- The effects of alpha-lipoic acid on glycemic control: a systematic review and meta-analysis. Akbari M, Ostadmohammadi V, Lankarani KB, et al.. Clinical Nutrition (2018)View study
Related Health Conditions
Related Supplements
Have questions about Alpha-Lipoic Acid (ALA)?
Ask Mother Nature AI about dosing, interactions with your medications, whether it fits your health goals, and more — personalized to your health profile.
This entry is for educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement regimen, especially if you take medications or have health conditions.